SARS-CoV-2 Alpha Variant Infection of a Patient Immunized by Inactive Sinovac (CoronaVac) Vaccine

Cenk Serhan Ozverel ^{1, 2}

Pinar Tulay ^{1, 3}

Mahmut Cerkez Ergoren ^{1, 3}

Emrah Guler ^{1, 4}

Buket Baddal ^{1, 5}

Kaya Suer ^{1, 6}

Tamer Sanlidag ¹

Hide authors affiliations

DESAM Institute , Near East University , Nicosia , Cyprus |

Department of Basic Medical Sciences, Faculty of Dentistry , Near East University , Nicosia , Cyprus |

Department of Medical Genetics, Faculty of Medicine , Near East University , Nicosia , Cyprus |

⁴

Department of Nutrition and Dietetics, Faculty of Health Sciences , Near East University , Nicosia , Cyprus |

⁵

Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine , Near East University , Nicosia , Cyprus |

⁶

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine , Near East University , Nicosia , Cyprus |

Publication type: Journal Article

Publication date: 2022-01-01

Walter de Gruyter

Journal: The EuroBiotech Journal

scimago Q3

SJR: 0.236

CiteScore: 3.6

Impact factor: 1.2

ISSN: 2564615X

DOI: 10.2478/ebtj-2022-0003

Copy DOI

Molecular Biology

Genetics

Molecular Medicine

Biotechnology

Food Science

Biomedical Engineering

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in December 2019, and shortly after pandemic has been declared by the World Health Organization (WHO) due to its unstoppable global spread. Considerable amount of effort has beenput around the World in order to develop a safe and effective vaccine against SARS-CoV-2. Inactivated and RNA vaccines have already passed phase three studies showing sufficient efficacy and safety, respectively. Nowadays, there is a noticeable dominance of SARS-CoV-2 variants with various mutations over the wild type SARS-CoV-2. However, there is no report showing the efficacy of these vaccines on these variants. This case study describes a thirty-eight-year-old male reported to be infected with SARS-CoV-2 alpha variant following two doses of inactive CoronaVac administration with a protective level of SARS-CoV-2 specific antibodies. The variant analysis of the virus reported to be positive for N501Y mutation.This is the first case in the literature demonstrating that inactive SARS-CoV-2 vaccine might have a lower efficacy on alpha variant.